Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
CognitivoSolo preclínico

Dihexa

Investigación publicada y base de evidencia

Dihexa (PNB-0408; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small, metabolically stabilised peptide derived from angiotensin IV by the Harding laboratory at Washington State University, reported in animal studies to cross the blood-brain barrier and to act through the hepatocyte growth factor (HGF)/c-Met receptor system. Independent rodent studies reported improved spatial memory and reduced neuroinflammation in APP/PS1 Alzheimer's mice and rescue of working memory after repeated mild brain injury, and a zebrafish study reported hair-cell protection, while a controlled rat study in a Huntington's disease-like model found no protective effect. Several of the developer laboratory's foundational papers, including the 2014 paper linking its procognitive effects to HGF/c-Met, were retracted in 2025, and the paper that introduced dihexa carries an expression of concern. No human study of dihexa has been published; the related HGF/MET modulator fosgonimeton reached a phase 2/3 Alzheimer's trial that did not meet its endpoints.

En resumen
  • Dihexa es un pequeño péptido derivado de la angiotensina IV.
  • Estudios en animales reportaron mejora de memoria en ratones Alzheimer y ratas con lesión cerebral.
  • No existen estudios humanos; artículos mecanísticos clave fueron retractados en 2025.

13 estudios · 3 desde 2023 · más reciente 2025

Estudios citados
13
Publicados en 2023+
3
Artículo más reciente
2025
Última revisión
oct 2026

Temas recurrentes en la literatura

  • HGF/c-Met positive modulation
  • angiotensin IV analogue
  • synaptogenesis and spatial memory in rodents
  • neuroinflammation and PI3K/AKT signalling
  • retracted foundational studies
  • no human trials

Identificadores del compuesto

CAS
1401708-83-5
PubChem
129010512

Identidad química

Qué es Dihexa, químicamente.

Fórmula molecular
C27H44N4O5
Peso molecular
504.7 g/mol
Número CAS
1401708-83-5
PubChem CID
129010512
También escrito como

PNB-0408

Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.

La evidencia

13 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Revisión sistemática2018

    Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies

    Ho JK, et al. · Neurosci Biobehav Rev · systematic review of 32 experimental (non-human) studies of angiotensin IV, angiotensin-(1-7) and their receptors

    Of 450 screened articles, 32 animal studies met inclusion criteria. In models of cognitive deficit, eight of nine studies reported that angiotensin IV and its analogues, including dihexa, improved performance on spatial working memory and passive avoidance tasks; the authors noted the peptides appeared most effective when given intracerebroventricularly close to learning or testing.

  2. 02Clínico humano2025

    Fosgonimeton in mild-to-moderate Alzheimer's disease

    Porsteinsson AP, et al. · J Alzheimers Dis Rep · LIFT-AD randomised, placebo-controlled phase 2/3 trial (NCT04488419), primary analysis n = 287, safety population n = 549, mild-to-moderate Alzheimer's disease; fosgonimeton, not dihexa

    Fosgonimeton did not achieve its primary endpoint or its secondary endpoints (ADAS-Cog11, ADCS-ADL23) at 26 weeks. Serious adverse events were balanced between groups, but more participants on fosgonimeton (14.2%) than placebo (4.6%) discontinued because of adverse events, mostly injection-site reactions.

    Hallazgo de seguridad reportado. Higher adverse-event discontinuation with fosgonimeton than placebo (14.2% vs 4.6%), mainly injection-site reactions; related compound, not dihexa.

  3. 03Clínico humano2022

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

    Hua X, et al. · J Alzheimers Dis · randomised, double-blind, placebo-controlled phase I trial (NCT03298672), 88 participants: healthy young men, healthy elderly and people with Alzheimer's disease; fosgonimeton (ATH-1017), a distinct HGF/MET positive modulator, not dihexa

    Fosgonimeton was reported to be safe and well tolerated, with dose-proportional pharmacokinetics and no accumulation over 9 days. It induced acute gamma-power changes on quantitative EEG, and in a small Alzheimer's subgroup ERP P300 latency moved toward normal compared with placebo.

    Hallazgo de seguridad reportado. Phase I safety and tolerability data for fosgonimeton, a related but distinct HGF/MET modulator; not applicable to dihexa directly.

  4. 04Animal in vivo2025

    Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury

    Martino KA, et al. · Neurotrauma Rep · closed-head midline impact model of repeated mild traumatic brain injury (species not stated in abstract); compound identified as dihexa by the record keywords

    Following repeated mild traumatic brain injury, the HGF/MET positive modulator dose-dependently rescued working memory deficits. The authors proposed the HGF/MET system as a pharmacological target for cognitive sequelae of brain injury.

  5. 05Animal in vivo2024

    Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats

    Wells RG, et al. · J Huntingtons Dis · 40 male Wistar rats, 3-nitropropionic acid model of Huntington's disease-like symptoms; vehicle, 3-NP and 3-NP plus PNB-0408 (dihexa) groups over five weeks

    3-nitropropionic acid reduced weight gain, impaired spatial learning and memory and caused marked motor dysfunction. Co-administration of PNB-0408 did not protect against any of these deficits, and the authors concluded it may not be efficacious in this model.

  6. 06Animal in vivo2021

    AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway

    Sun X, et al. · Brain Sci · APP/PS1 transgenic Alzheimer's disease mice, oral dihexa versus wild-type and vehicle controls

    Dihexa restored spatial learning in the Morris water maze, increased neuronal counts and synaptophysin expression, reduced astrocyte and microglial activation, and lowered IL-1beta and TNF-alpha while raising IL-10. These effects were reversed by the PI3K inhibitor wortmannin, implicating PI3K/AKT signalling.

  7. 07Animal in vivo2021

    Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies

    Weiss JB, et al. · Ann Med Surg (Lond) · male Lewis rats, sciatic nerve transection and repair; 10 groups (n = 6-8 per group) receiving mesenchymal stem cells, G-CSF and/or dihexa locally or systemically over 16 weeks

    Sensory function returned to near normal by 8 weeks in all groups combined. Motor function at 8-16 weeks improved significantly with mesenchymal stem cells plus G-CSF or mesenchymal stem cells plus dihexa delivered into the gastrocnemius muscle, which also reduced foot flexion contractures.

  8. 08Animal in vivo2015

    Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure

    Uribe PM, et al. · Front Cell Neurosci · larval zebrafish lateral line hair cells exposed to neomycin or gentamicin

    Dihexa protected hair cells from aminoglycoside toxicity without reducing aminoglycoside uptake. Protection was attenuated by the HGF antagonist 6-AH and by inhibitors of Akt, TOR and MEK, consistent with an HGF/c-Met-mediated mechanism; adding an amino group to dihexa's N-terminus reduced the effect.

  9. 09Animal in vivo2011

    Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs

    Benoist CC, et al. · J Pharmacol Exp Ther · rats, scopolamine-induced spatial memory deficit (Morris water maze) and hippocampal dendritic spine analysis; Nle1-angiotensin IV-derived tetra- and tripeptides (dihexa precursors)

    Nle1-angiotensin IV-derived peptides as small as tetra- and tripeptides reversed scopolamine-induced deficits in Morris water maze performance. Procognitive activity correlated with each peptide's capacity to increase dendritic spine number and spine head size.

  10. 10In vitro2022

    Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy

    Pan T, et al. · Stem Cell Res Ther · human pluripotent stem cells differentiated to hepatocyte-like cells using a small-molecule-only protocol

    A combination of vitamin C, dihexa and forskolin substituted for recombinant growth factors to induce hepatic specification. The resulting hepatoblasts expanded and matured into functional hepatocyte-like cells that repopulated injured liver in vivo.

  11. 11In vitro2010

    The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor

    Yamamoto BJ, et al. · J Pharmacol Exp Ther · mouse liver membranes and multiple cell types, with ex vivo angiogenesis and B16-F10 melanoma lung colonisation assays; angiotensin IV analogue norleual (context compound, not dihexa)

    The angiotensin IV analogue norleual competitively inhibited HGF binding to c-Met at picomolar concentrations and blocked HGF-dependent signalling, proliferation, migration and invasion. It showed antiangiogenic activity and suppressed pulmonary colonisation by melanoma cells, supporting the hypothesis that angiotensin IV analogues act through the HGF/c-Met system.

  12. 12Revisión2015

    The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease

    Wright JW, et al. · J Alzheimers Dis · narrative review from the originating laboratory

    The review described the brain HGF/c-Met receptor system as a therapeutic target in Alzheimer's disease and summarised animal data on dihexa, a Nle1-angiotensin IV-derived small molecule reported to be orally active, to penetrate the blood-brain barrier and to promote synaptogenesis and memory consolidation in animal models.

  13. 13Revisión2015

    The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

    Wright JW, et al. · Prog Neurobiol · narrative review from the originating laboratory

    The review summarised brain renin-angiotensin system research in learning, memory and motor function and noted unresolved controversy over the identity of the AT4 receptor (insulin-regulated aminopeptidase versus the HGF/c-Met system). It described metabolically stable, blood-brain barrier-penetrant angiotensin IV-based small molecules tested in animal models of Alzheimer's and Parkinson's disease.

Limitaciones

Lo que esta evidencia no establece.

No clinical trial, pharmacokinetic study or safety study of dihexa in humans has been published, and all efficacy data come from rodent, zebrafish and cell models. The mechanistic case rests heavily on papers from the originating laboratory, two of which were retracted in 2025 and one of which carries an expression of concern, so the HGF/c-Met mechanism has limited independent confirmation. Long-term safety, including theoretical concerns from sustained activation of the growth-promoting HGF/c-Met pathway, has not been studied, and a closely related HGF mimetic was ototoxic in mice.

Preguntas comunes sobre la investigación.

What is Dihexa?

Dihexa (PNB-0408) is a small, metabolically stabilised peptide derived from angiotensin IV by a laboratory at Washington State University. Animal studies reported that it crosses the blood-brain barrier and acts through the hepatocyte growth factor (HGF)/c-Met receptor system. It has not been studied in humans.

Why do some Dihexa papers carry retraction notices?

Two papers from the originating laboratory, published in 2012 and 2014, linked the effects of dihexa and related angiotensin IV analogues to the HGF/c-Met system; both were retracted in April 2025. The 2013 paper that introduced dihexa carries a 2021 expression of concern. None of these papers is cited on this page. The remaining independent work is in animals, including an Alzheimer's mouse model and a repeated brain-injury model, and one controlled rat study in a Huntington's disease-like model found no protective effect.

Has Dihexa been tested in humans?

No human study of dihexa has been published. The closest human data come from fosgonimeton, a different HGF/MET positive modulator from the same developer: a phase 1 trial reported it was well tolerated, and the phase 2/3 LIFT-AD trial in mild-to-moderate Alzheimer's disease did not meet its primary or secondary endpoints. Those results describe fosgonimeton and cannot be read as evidence about dihexa itself.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.